Article Text

Download PDFPDF
Saving the critically ill trauma patient
  1. Melvyn Harris, M.D
  1. Correspondence to Dr Melvyn Harris, Loma Linda University Medical Center, Division of Emergency Medicine, Loma Linda, CA, USA; harrist21{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the Editor;

The article titled ‘Saving the critically injured trauma patient: a retrospective analysis of 1000 uses of intraosseous access’1 reaches conclusions that are not supported by their data or other existing literature.

Existing scientific evidence is inadequate to support the authors’ implication of equivalency between intravenous and intraosseous (IO) routes.2 ,3 For example, in table 1, the authors state that tranexamic acid was administered to 82 casualties with no evidence of complications. But, there is no evidence of therapeutic equivalence between IO-administered tranexamic acid and intravenously administered tranexamic acid. To date, no …

View Full Text


  • Correction notice The competing interests statement in this letter has been updated since it was first published online.

  • Competing interests MH is a Co-Founder, shareholder, and former Chair and Chief Medical Officer of Evena Med which designs and manufactures multi-spectral near infrared light imaging technology for multiple medical applications including vascular access. Evena Med is also an OEM (original equipment manufacturer) for a privately held manufacturer of point of care ultrasound technology.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles